Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise in recent clinical trials. Nuclease-driven genome editing provides a method in which to precisely target genetic changes to further enhance T cell function in vivo. We describe the development of a highly efficient method to genome edit both primary human CD8 and CD4 T cells by homology-directed repair at a pre-defined site of the genome. Two different homology donor templates were evaluated, representing both minor gene editing events (restriction site insertion) to mimic gene correction, or the more significant insertion of a larger gene cassette. By combining zinc finger nuclease mRNA delivery with AAV6 delivery of a homologous donor we could gene correct 41% of CCR5 or 55% of PPP1R12C (AAVS1) alleles in CD8(+) T cells and gene targeting of a GFP transgene cassette in >40% of CD8(+) and CD4(+) T cells at both the CCR5 and AAVS1 safe harbor locus, potentially providing a robust genome editing tool for T cell-based immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Additional work has demonstrated that Adeno Associated Virus Serotype 6 (AAV6) functions as a highly efficient DNA template donor for homologous recombination (HR) in both hematopoietic stem cells and T cells15,16.”
From Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease (2018) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 2×
“Merged reads were filtered using the following criteria: the 5 and 3 ends (23 bp) must match the expected amplicon exactly, the read must not map to a different lo-cus in the target genome as determined by Bowtie2 (24) with default settings, and deletions must be 70% of the amplicon size or 70 bp long.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820 · cited 1×
“…nucleases (TALENs), and the RNA-guided clustered regularly interspaced short palindromic repeat (CRISPR) / Cas endonucleases, are a powerful class of enzymes that promote genome editing through the creation of a site-specific DNA double-strand break (DSB) at a pre-defined site in the genome (8).”
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506 · cited 1×
“Nucleic Acids Research, 2016, Vol. 44, No. 3 e30 CD8 + cytotoxic T lymphocytes (CTLs) have been proven to exhibit potent anti-tumor activity in preclinical and clinical studies (1–2 , 26– 28 ).”
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388 · cited 2×
“Furthermore, Engineered CD19-specific CD4 + T cell responses comprised at least part of the anti-tumor effects against B-cell malignance in a few of the recent successful clinical trials (26-28).”
Cited by
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“Co-delivery Co-delivery of Cas9 mRNA and sgRNA or ZFN mRNA for ex vivo gene editing can be achieved via physical methods that bypass the extracellular and cytoplasmic barriers to deposit the molecular cargoes, such as electroporation 145,146 or microinjection into embryos.”
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
Next-generation regulatory T cell therapy
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 476
Programming CAR-T cells to kill cancer
Labanieh, L., Majzner, R. G., & Mackall, C. L. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0235-9 · Cited by 431
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak, R. O., Dever, D. P., & Porteus, M. H. (2018) · Nature Protocols · doi:10.1038/nprot.2017.143 · Cited by 319
MacLeod, D. T., Antony, J., Martin, A. J., Moser, R. J., Hekele, A., Wetzel, K. J., Brown, A. E., Triggiano, M. A., Hux, J. A., Pham, C. D., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.005 · Cited by 276
“Also consistent with other reports is our observation of a striking increase in gene expression following integration into the genome.(25,26) Figures 2B and 3D show marked increases in gene expression 3 days post-transduction in cells that were electroporated with TRC1-2 mRNA compared with cells that were mock-electro…”
ResultGenome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Zhang, H.-X., Zhang, Y., & Yin, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.014 · Cited by 248
CAR T cells for infection, autoimmunity and allotransplantation
Maldini, C. R., Ellis, G. I., & Riley, J. L. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0042-2 · Cited by 229
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez-Gascón, A., Solinís, M. Á., & del Pozo-Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 223
Gene editing for immune cell therapies
Bailey, S. R., & Maus, M. V. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0137-8 · Cited by 203
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
Moffett, H. F., Coon, M. E., Radtke, S., Stephan, S. B., McKnight, L., Lambert, A., Stoddard, B. L., Kiem, H. P., & Stephan, M. T. (2017) · Nature Communications · doi:10.1038/s41467-017-00505-8 · Cited by 183
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 180
“Regarding the original transposon vector, referred to as pT, the modification of nucleotide residues within the ITR sequences by means of mutations, additions or deletions have give rise to in improved versions such as pT2, pT3, pT2B, and, lastly, pT4 (65, 66), which has an optimized donor vector architecture.”
MethodGenetic engineering of T cells for immunotherapy
Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 162
“Viral: 40–60% on a non-clinical scale(85,224) Immunogenicity of DNA or AAV, off-target integration; dependent on presence of adjacent PAM Integration of large cargoes AAVS1 (reF.(100)) Safe harbour site for genome integration”
BackgroundOff-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma
Brown, C. E., Rodriguez, A., Palmer, J. M., Ostberg, J. R., Naranjo, A., Wagner, J. R., Aguilar, B., Starr, R., Weng, L., Synold, T. W., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac024 · Cited by 167
Self-citationOne-step generation of modular CAR-T cells with AAV–Cpf1
Dai, X., Park, J. J., Du, Y., Kim, H. R., Wang, G., Errami, Y., & Chen, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0329-7 · Cited by 160
Morgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 157
Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome
Hubbard, N., Hagin, D., Sommer, K., Song, Y., Khan, I., Clough, C., Ochs, H. D., Rawlings, D. J., Scharenberg, A. M., & Torgerson, T. R. (2016) · Blood · doi:10.1182/blood-2015-11-683235 · Cited by 138
Non-Viral Delivery To Enable Genome Editing
Rui, Y., Wilson, D. R., & Green, J. J. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.08.010 · Cited by 113
“For gene insertion applications, the need for a donor template DNA may also necessitate an alternative delivery mechanism as Wang and colleagues demonstrated when the authors used electroporation to deliver mRNA coding for ZFNs and a viral vector to deliver donor DNA [43].”
BackgroundSystemic mRNA delivery to the lungs by functional polyester-based carriers
Yan, Y., Xiong, H., Zhang, X., Cheng, Q., & Siegwart, D. J. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01356 · Cited by 111
Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology
Weng, Y., Huang, Q., Li, C., Yang, Y., Wang, X., Yu, J., Huang, Y., & Liang, X.-J. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.12.004 · Cited by 107
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
Foster, J. B., Barrett, D. M., & Karikó, K. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.018 · Cited by 97
Delivery technologies for T cell gene editing: Applications in cancer immunotherapy
Atsavapranee, E., Billingsley, M. M., & Mitchell, M. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103354 · Cited by 111
Westhaus, A., Cabanes-Creus, M., Rybicki, A., Baltazar, G., Navarro, R. G., Zhu, E., Drouyer, M., Knight, M., Albu, R. F., Ng, B. H., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.264 · Cited by 102
“Based on published results, AAV6 was expected to functionally transduce primary T cells with superior efficiency.(43,50) However in our NGS screen, it only contributed 23% of the total RNA reads, substantially less than the 60% observed for AAV 7m8 (Fig.”
ResultGoing non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
Hudecek, M., Izsvák, Z., Johnen, S., Renner, M., Thumann, G., & Ivics, Z. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1304354 · Cited by 92
“Finally, optimization of SB transposase binding to its internal binding sites within the transposon TIRs by cyclic amplification and selection of targets (CASTing) recently yielded pT4 with modest hyperactivity (Wang et al., 2016b).”
BackgroundMethodInfluentialEngineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
Johnson, M. J., Laoharawee, K., Lahr, W. S., Webber, B. R., & Moriarity, B. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30358-0 · Cited by 92
Pattabhi, S., Lotti, S. N., Berger, M. P., Singh, S., Lux, C. T., Jacoby, K., Lee, C., Negre, O., Scharenberg, A. M., & Rawlings, D. J. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.05.025 · Cited by 91
Gaj, T., Staahl, B. T., Rodrigues, G. M. C., Limsirichai, P., Ekman, F. K., Doudna, J. A., & Schaffer, D. V. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx154 · Cited by 89
High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA
Oh, S. A., Senger, K., Madireddi, S., Akhmetzyanova, I., Ishizuka, I. E., Tarighat, S., Lo, J. H., Shaw, D., Haley, B., & Rutz, S. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211530 · Cited by 88
“Viral vectors, in particular adeno-associated viruses (AAV), have been used to deliver donor DNA templates for HDRmediated target gene knock-in in T cells (Sather et al., 2015; Wang et al., 2016; Eyquem et al., 2017; Choi et al., 2019).”
MethodCRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 74
Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding
Jarrell, J. A., Twite, A. A., Lau, K. H. W. J., Kashani, M. N., Lievano, A. A., Acevedo, J., Priest, C., Nieva, J. J., Gottlieb, D. J., & Pawell, R. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-40147-y · Cited by 73
“This includes constructs to engineer immune cells in a permanent 28,31 , long lived 27,32 , or transient manner 29,30 .”
BackgroundOptimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV
Kararoudi, M. N., Likhite, S. B., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., Pereira, M. D. S. F., Sezgin, Y., Devine, R. D., Lyberger, J. M., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100236 · Cited by 73
“…of the flanking regions of the Cas9 targeting site in the AAVS1 locus, cloned these together with the mCherry gene into the backbone of a single-stranded AAV plasmid, and packaged this construct into the AAV6 viral capsid (Figure 2A) (Foust et al., 2013; Wang et al., 2016; Eyquem et al., 2017).”
BackgroundMethodThe Role of Recombinant AAV in Precise Genome Editing
Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.799722 · Cited by 69
“In the presence of correction DNA templates bearing homology to the target genomic sequence, a fraction of DSBs were found to undergo HR-based editing (Vasileva et al., 2006; Wang et al., 2016; Smith et al., 2018), resulting in a recent proliferation of programmable nuclease-based editing platforms.”
BackgroundIn vivo site-specific engineering to reprogram T cells
Nyberg, W. A., Bernard, P.-L., Ngo, W., Wang, C. H., Ark, J., Rothrock, A., Borgo, G. M., Kimmerly, G. R., Jung, J. H., Allain, V., et al. (2026) · Nature · doi:10.1038/s41586-026-10235-x · Cited by 70
“Human T cells were co-cultured with the capsid library at a low MOI in the presence of human serum, which is known to limit AAV6 transduction due to neutralizing antibody 35,36 .”
Sachdeva, M., Busser, B. W., Temburni, S., Jahangiri, B., Gautron, A.-S., Maréchal, A., Juillerat, A., Williams, A., Depil, S., Duchateau, P. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13088-3 · Cited by 67
Dever, D. P., & Porteus, M. H. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000385 · Cited by 62
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100304 · Cited by 62
“They have also been used successfully to edit specific gene targets in T cells and insert larger gene cassettes using a viral vector (49).”
MethodCRISPR-Based Tools in Immunity
Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 63
Fakhiri, J., Schneider, M. A., Puschhof, J., Stanifer, M., Schildgen, V., Holderbach, S., Voss, Y., El Andari, J., Schildgen, O., Boulant, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.003 · Cited by 56
Bhagwan, J. R., Collins, E. M., Mosqueira, D., Bakar, M., Johnson, B. B., Thompson, A., Smith, J. G. W., & Denning, C. N. (2019) · F1000Research · doi:10.12688/f1000research.19894.2 · Cited by 60
Genome editing for inborn errors of metabolism: advancing towards the clinic
Schneller, J. L., Lee, C. M., Bao, G., & Venditti, C. P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0798-4 · Cited by 64
“In human-derived models, parallel efforts have successfully integrated therapeutic cDNA into the AAVS1 site in stem cells [46] and T cells [47]; the ongoing transcriptional activity of transgenes inserted in AAVS1 makes it a plausible target [48].”
BackgroundCRISPR-Cas Targeting of Host Genes as an Antiviral Strategy
Chen, S., Yu, X., & Guo, D. (2018) · Viruses · doi:10.3390/v10010040 · Cited by 57
“Compared to other AAV subtype vectors, only AAV6 achieved efficient gene editing in transduced primary T cells and CD34 + hematopoietic cells [88] [89] [90] .”
BackgroundMethodTargeted Gene Delivery: Where to Land
Pavani, G., & Amendola, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.609650 · Cited by 55
“Beside HSC and terminally differentiated blood cells, like B and T cells (Wang et al., 2016; Hung et al., 2018), AAV and nucleases have been the preferred method to achieve targeted transgene integration in many tissues in vivo (Suzuki et al.”
BackgroundMethodOptimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity
Lam, A. J., Lin, D. T. S., Gillies, J. K., Uday, P., Pesenacker, A. M., Kobor, M. S., & Levings, M. K. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109494 · Cited by 52
“A wide range of AAV6 titers and delivery time points have been reported for HDR editing in human T cells, from 10(3) to 10(6) viral genomes (vg)/cell and addition within minutes to hours after electroporation (Eyquem et al., 2017; Gwiazda et al., 2016; Hale et al., 2017; Sather et al., 2015; Wang et al., 2016).”
Vavassori, V., Mercuri, E., Marcovecchio, G. E., Castiello, M. C., Schiroli, G., Albano, L., Margulies, C. M., Buquicchio, F. A., Fontana, E., Beretta, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013545 · Cited by 53
“Efficient and functional CD40LG correction of human CD4 HIGM1 T cells We produced an AAV6 delivery vehicle for the selected HDR donor template (Wang et al, 2016) (Fig 1B) and optimized RNP and AAV6 dose for maximizing editing efficiency (Fig EV1K–”
MethodWang, Q., Chen, S., Xiao, Q., Liu, Z., Liu, S., Hou, P., Zhou, L., Hou, W., Ho, W., Li, C., et al. (2017) · Retrovirology · doi:10.1186/s12977-017-0375-0 · Cited by 54
Optimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50
“Subsequent studies then demonstrated that AAV6 could efficiently transduce human CD34+ hematopoietic progenitor cells [172] and CD4+ T cells [173, 174], and AAV6 is now the vector of choice for many to deliver gene-editing enzymes or knock-in donors to primary T cells in the generation of CAR T cells or HIV receptor k…”
BackgroundSite-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
Dabiri, H., Kozani, P. S., Habibi‐Anbouhi, M., Godarzee, M. M., Haddadi, M. H., Basiri, M., Ziaei, V., Sadeghizadeh, M., & Saffar, E. H. (2023) · Biomarker Research · doi:10.1186/s40364-023-00509-1 · Cited by 49
“When they attempted to prepare a CAR expression cassette using plasmid DNA or PCR products as the template, the efficiency of gene integration was less than 10-fold in comparison with an AAV [91].”
BackgroundResultExploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1286 · Cited by 39
Engineered Treg cells: The heir to the throne of immunotherapy
Stucchi, A., Maspes, F., Montee-Rodrigues, E., & Fousteri, G. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102986 · Cited by 46
Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
Gao, T. A., & Chen, Y. Y. (2022) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-092120-092914 · Cited by 44
Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes
Rogers, G. L., Huang, C., Clark, R. D. E., Seclén, E., Chen, H.-Y., & Cannon, P. M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.003 · Cited by 42
“In the original protocol, cells are electroporated first, then transduced with AAV6-CCR5-GFP using standard cell culture concentrations prior to addition of FBS.”
MethodInfluentialGene therapy for blood diseases
Kohn, D. B. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.11.016 · Cited by 39
Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors
Hamann, M. V., Beschorner, N., Vu, X., Hauber, I., Lange, U. C., Traenkle, B., Kaiser, P. D., Foth, D., Schneider, C., Büning, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261269 · Cited by 39
“We included the latter because of reports about AAV6’s ability to transduce various human primary cells, including dendritic cells (DC), CD34 + hematopoietic stem and progenitor cells (HSC), and CD8 + and CD4 + T cells [45–47].”
Guo, T., Ma, D., & Lu, T. K. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00236 · Cited by 37
Zhou, Z. P., Yang, L., Cao, H., Chen, Z. R., Zhang, Y., Wen, X., & Hu, J. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.074 · Cited by 38
Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing
Smith, L. J., Wright, J. B., Clark, G., Ul-Hasan, T., Jin, X., Fong, A., Chandra, M., Martin, T. S., Rubin, H. L., Knowlton, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802343115 · Cited by 36
Genome Engineering with TALE and CRISPR Systems in Neuroscience
Lee, H. B., Sundberg, B. N., Sigafoos, A. N., & Clark, K. J. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00047 · Cited by 41
“…DSBs in the genomic target locus (Urnov et al., 2005; Beumer et al., 2008; Greenwald et al., 2010; Li et al., 2013; Zu et al., 2013; Gratz et al., 2014; Krentz et al., 2014; Platt et al., 2014; Shin et al., 2014a; Xie F. et al., 2014a; Karakikes et al., 2015; Lee et al., 2015; Wang et al., 2016).”
BackgroundIn vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313
Nyberg, W. A., Wang, C. H., Ark, J., Liu, C., Clouden, S., Qualls, A., Caryotakis, S. E., Wells, E., Simon, K. E., Garza, C., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.009 · Cited by 34
Shakirova, A. I., Karpov, T. E., Komarova, Y., & Lepik, K. V. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1068637 · Cited by 34
“Some reports claimed that using asymmetric homology arms appeared to be more efficient for editing of certain genes (Wang et al., 2016; MacLeod et al., 2017).”
BackgroundIn vivo manufacture and manipulation of CAR-T cells for better druggability
Hou, R., Zhang, X., Wang, X., Zhao, X., Li, S., Guan, Z., Cao, J., Liu, D., Zheng, J., & Shi, M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10185-8 · Cited by 32
“Among numerous serotypes and variants, Serotype 6 (AAV6) is considered the most suitable serotype for the transduction of T cells due to its superior transduction efficiency of over 75% for both CD4 + and CD8 + T cells [25, 26].”
Gene editing and its application for hematological diseases
Osborn, M. J., Belanto, J. J., Tolar, J., & Voytas, D. F. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2017-z · Cited by 36
Adeno‐Associated Viral Vectors for Homology‐Directed Generation of CAR‐T Cells
Moço, P. D., Aharony, N., & Kamen, A. (2019) · Biotechnology Journal · doi:10.1002/biot.201900286 · Cited by 28
Viney, L., Bürckstümmer, T., Eddington, C., Mietzsch, M., Choudhry, M. S., Henley, T., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.02023-20 · Cited by 27
“However, despite the advances in AAV 96 vector engineering, capsid evolution, and use of synergistic technologies such as CRISPR, 97 high AAV dose MOIs, typically 1x10(6) virus particles per cell, are still required for gene 98 delivery into cells being modified for either research or therapeutic applications (19).”
BackgroundHoughton, B. C., Panchal, N., Haas, S. A., Chmielewski, K. O., Hildenbeutel, M., Whittaker, T. E., Mussolino, C., Cathomen, T., Thrasher, A. J., & Booth, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.828489 · Cited by 28
Electrotransfer for nucleic acid and protein delivery
Muralidharan, A., & Boukany, P. E. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.11.009 · Cited by 26
Liu, J., & Shui, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.014 · Cited by 28
Rogers, G. L., Chen, H.-Y., Morales, H., & Cannon, P. M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.019 · Cited by 24
Liu, T., Hu, Y., Guo, S., Tan, L., Zhan, Y., Yang, L., Liu, W., Wang, N., Li, Y., Zhang, Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192641 · Cited by 23
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Cell and gene therapy strategies to eradicate HIV reservoirs
Spragg, C. J., Feelixge, H. S. D. S., & Jerome, K. R. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000284 · Cited by 25
Applications of CRISPR-Cas in Bioengineering, Biotechnology, and Translational Research
Lau, C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0026 · Cited by 24
“223 In earlier studies, ZFNs 224–226 and TALENs 227,228 have also helped to unleash the therapeutic potential of CAR-T cell therapy by genetically editing the T cell.”
Lindel, F., Dodt, C., Weidner, N., Noll, M., Bergemann, F., Behrendt, R., Fischer, S., Dietrich, J., Cartellieri, M., Hamann, M. V., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.006 · Cited by 22
Application of Genome Editing Techniques in Immunology
Zych, A. O., Bajor, M., & Zagożdżon, R. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-018-0504-z · Cited by 26
“2008), especially when combined with adenoassociated virus vectors to function as homology donors (Wang et al. 2016).”
BackgroundStone, D., Kenkel, E. J., Loprieno, M. A., Tanaka, M., Feelixge, H. S. D. S., Kumar, A. J., Stensland, L., Obenza, W., Wangari, S., Ahrens, C. Y., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.113 · Cited by 21
Ely, A., Singh, P., Smith, T. S., & Arbuthnot, P. B. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.010 · Cited by 22
Germline T cell receptor exchange results in physiological T cell development and function
Rollins, M. R., Raynor, J. F., Miller, E. A., Butler, J. Z., Spartz, E. J., Lahr, W. S., You, Y., Burrack, A. L., Moriarity, B. S., Webber, B. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36180-1 · Cited by 18
Kruglova, N. A., & Shepelev, M. V. (2024) · Biomedicines · doi:10.3390/biomedicines12010119 · Cited by 18
“Donor DNA in the linear form In comparison to the AAV6 production, donor DNA in the form of dsDNA can be obtained more rapidly as a PCR product, a restriction plasmid product or, less commonly, as a circular plasmid DNA.”
BackgroundMoço, P. D., Xu, X., Silva, C. A. T., & Kamen, A. (2023) · Biotechnology Journal · doi:10.1002/biot.202300051 · Cited by 19
Structural basis for nuclear import of adeno-associated virus serotype 6 capsid protein
Hoad, M., Nematollahzadeh, S., Petersen, G. F., Roby, J. A., Alvisi, G., & Forwood, J. K. (2024) · Journal of Virology · doi:10.1128/jvi.01345-24 · Cited by 17
Chatterjee, S., Sivanandam, V., & Wong, K. K. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.049 · Cited by 17
Kararoudi, M. N., Likhite, S. B., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., Pereira, M. D. S. F., Devin, R. D., Lyberger, J. M., Behbehani, G. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.17.435886 · Cited by 16
Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors
Lo Presti, V., Buitenwerf, F., van Til, N. P., & Nierkens, S. (2020) · Vaccines · doi:10.3390/vaccines8040733 · Cited by 14
“Adeno associated viral (AAV) vectors have been used as DNA donor sequence delivery system, especially serotype AAV6 [48], particularly efficient to provide HR compared to other viral systems, such as integration deficient lentiviral vectors [49].”
MethodGene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases
Rogers, G. L., & Cannon, P. M. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.008 · Cited by 16
Optimization and Validation of CAR Transduction into Human Primary NK Cells Using CRISPR and AAVPreprint
Kararoudi, M. N., Likhite, S. B., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., Pereira, M. D. S. F., Devin, R. D., Lyberger, J. M., Behbehani, G. K., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3869896 · Cited by 13
Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV-CAR-T cells
Wang, D., Zhou, Q., Qiu, X., Liu, X., & Zhang, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113027 · Cited by 12
T-cell tweaks to target tumours
Maus, M. V. (2017) · Nature · doi:10.1038/nature21506 · Cited by 11
Clinical Applications of Genome Editing to HIV Cure
Wang, C. X., & Cannon, P. M. (2016) · AIDS Patient Care and STDs · doi:10.1089/apc.2016.0233 · Cited by 13
“Using this method, HR efficiencies of up to 40–60% have been achieved in primary T cells and HSPCs at the CCR5, IL2RgG, HBB, and AAVS1 loci.(37,45,56,57) Nevertheless, HR efficiencies vary widely by loci and nature of template, with the highest efficiencies resulting from editing of AAVS1, the natural AAV integration…”
MethodDavid, M., Monteferrario, D., Saviane, G., Jeanneau, C., Marchetti, I., Dupont, C. F., Dumont, C., Fontenot, J. D., de la Rosa, M., & Fenard, D. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101111 · Cited by 10
“AAV6-GFP and AAV6-FIX-Padua vectors were produced using a triple transfection method as previously described.(7) Briefly, HEK293 cells were transfected using the calcium phosphate method with an AAV Rep2/ Cap6 helper plasmid, the pXX6 adenovirus helper plasmid, and an ITR-containing donor vector plasmid.”
Selecting a Cell Engineering Methodology During Cell Therapy Product Development
Timmins, L. M., Burr, A., Carroll, K., Keefe, R., Teryek, M., Cantolupo, L. J., van der Loo, J. C. M., Heathman, T. R. J., Gormley, A. J., Smith, D. W., et al. (2021) · Cell Transplantation · doi:10.1177/09636897211003022 · Cited by 11
Moço, P. D., Dash, S., & Kamen, A. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3627 · Cited by 9
“12,19 Cell-penetrating peptides (CPPs) are short peptides capable of translocating across cellular membranes and transporting various cargoes into the cell, including drugs, therapeutic proteins, nucleases, plasmid DNA, nucleic acids and nanoparticles.”
BackgroundMethodStrategies and mechanisms of precision genome engineering: From gene editing to genome writing
Huang, K., Tian, J., Zhao, W., Zhang, S., Xiang, L., Yang, M., Ls, L., Huang, Y., Zhang, N., Sun, L., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70115 · Cited by 10
Moço, P. D., Farnós, O., Sharon, D. M., & Kamen, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100486 · Cited by 9
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
“79 They used ZFN — provided as mRNA — to modify the chemokine ( C-C motif) receptor 5 ( CCR5 ) gene.”
Metadata
- Authors
- Wang, J., DeClercq, J. J., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Gregory, P. D., Lee, G., & Holmes, M. C.
- Affiliations
- Sangamo BioSciences (United States) (US)
- Corresponding author
- Wang, Jianbin
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-02
- Volume
- 44
- Issue
- 3
- Pages
- e30-e30
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC4756813
- OpenAlex
- W1909557371
- Semantic Scholar
- 9f6bb7afb7fabc85e007197bcf8398372df2e5ee
- Cited by
- 128
- References
- 54
- Citations by year
- 2026: 11 · 2025: 2 · 2024: 7 · 2023: 14 · 2022: 13 · 2021: 14 · 2020: 11 · 2019: 18 · 2018: 16 · 2017: 13 · 2016: 9
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nucleic Acids Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- genome editing, human T cells, zinc finger nucleases, AAV6 vector, homology-directed repair, CCR5, AAVS1 safe harbor, CD8+ T cells, CD4+ T cells, gene correction, adoptive T cell therapy, T cell engineering
- MeSH terms
- Dependovirus, Endonucleases, Genetic Vectors, Humans, RNA, Messenger, Transfection, CD4-Positive T-Lymphocytes, Genome, Human, Zinc Fingers, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.